Pitcairn Co. Sells 8,216 Shares of Alexion Pharmaceuticals, Inc. (ALXN)

Pitcairn Co. reduced its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 28.7% during the first quarter, Holdings Channel reports. The institutional investor owned 20,431 shares of the biopharmaceutical company’s stock after selling 8,216 shares during the period. Pitcairn Co.’s holdings in Alexion Pharmaceuticals were worth $2,477,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Mutual of America Capital Management LLC boosted its position in Alexion Pharmaceuticals by 3.9% in the first quarter. Mutual of America Capital Management LLC now owns 27,995 shares of the biopharmaceutical company’s stock worth $3,394,000 after buying an additional 1,049 shares during the period. State of Wisconsin Investment Board boosted its position in Alexion Pharmaceuticals by 24.8% in the first quarter. State of Wisconsin Investment Board now owns 138,296 shares of the biopharmaceutical company’s stock worth $16,767,000 after buying an additional 27,477 shares during the period. State of Tennessee Treasury Department boosted its position in Alexion Pharmaceuticals by 123.9% in the first quarter. State of Tennessee Treasury Department now owns 206,344 shares of the biopharmaceutical company’s stock worth $25,017,000 after buying an additional 114,165 shares during the period. Warren Averett Asset Management LLC purchased a new position in Alexion Pharmaceuticals during the first quarter worth about $229,000. Finally, Toronto Dominion Bank boosted its position in Alexion Pharmaceuticals by 56.7% in the first quarter. Toronto Dominion Bank now owns 60,607 shares of the biopharmaceutical company’s stock worth $7,346,000 after buying an additional 21,938 shares during the period. Institutional investors and hedge funds own 94.98% of the company’s stock.

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded down 2.43% on Friday, reaching $113.84. 2,613,737 shares of the company’s stock were exchanged. Alexion Pharmaceuticals, Inc. has a 52-week low of $109.12 and a 52-week high of $157.02. The firm’s 50 day moving average price is $121.19 and its 200 day moving average price is $124.94. The company has a market cap of $25.56 billion, a PE ratio of 54.24 and a beta of 1.39.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, April 27th. The biopharmaceutical company reported $1.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.33. The company had revenue of $870 million for the quarter, compared to the consensus estimate of $826.63 million. Alexion Pharmaceuticals had a net margin of 12.46% and a return on equity of 10.58%. The firm’s revenue was up 24.3% compared to the same quarter last year. During the same quarter last year, the firm posted $1.11 earnings per share. On average, analysts expect that Alexion Pharmaceuticals, Inc. will post $5.31 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Pitcairn Co. Sells 8,216 Shares of Alexion Pharmaceuticals, Inc. (ALXN)” was posted by Mideast Time and is owned by of Mideast Time. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.mideasttime.com/pitcairn-co-sells-8216-shares-of-alexion-pharmaceuticals-inc-alxn/1708174.html.

A number of equities analysts have issued reports on the company. Royal Bank of Canada set a $187.00 target price on Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, January 21st. Raymond James Financial, Inc. restated a “strong-buy” rating and set a $176.00 price objective on shares of Alexion Pharmaceuticals in a research note on Tuesday, May 9th. Cowen and Company restated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Thursday, February 16th. Oppenheimer Holdings Inc. started coverage on shares of Alexion Pharmaceuticals in a research note on Wednesday, February 8th. They set a “hold” rating for the company. Finally, Barclays PLC restated an “overweight” rating and set a $155.00 price objective on shares of Alexion Pharmaceuticals in a research note on Tuesday, May 9th. Seven research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $168.10.

In other Alexion Pharmaceuticals news, Director Leonard Bell sold 3,978 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $131.96, for a total transaction of $524,936.88. Following the transaction, the director now owns 391,910 shares of the company’s stock, valued at $51,716,443.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Heidi L. Wagner sold 994 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $131.65, for a total transaction of $130,860.10. Following the transaction, the senior vice president now directly owns 29,646 shares in the company, valued at approximately $3,902,895.90. The disclosure for this sale can be found here. In the last three months, insiders sold 11,476 shares of company stock worth $1,504,601. 4.41% of the stock is currently owned by insiders.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

5 Day Chart for NASDAQ:ALXN

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.